342603-10-5

Basic information

• Product Name: N-BOC-3-AMINO-5-METHOXYPYRIDINE
• Synonyms: tert-butyl N-(5-Methoxypyridin-3-yl)carbaMate;(5-Methoxy-pyridin-3-yl)-carbamic acid tert-butyl ester;N-BOC-3-AMINO-5-METHOXYPYRIDINE;3-Boc-aMino-5-Methoxypyridine;Carbamic acid, N-(5-methoxy-3-pyridinyl)-, 1,1-dimethylethyl ester
• CAS NO: 342603-10-5
• Molecular Formula: C₁₁H₁₆N₂O₃
• Molecular Weight: 224.26
• Mol File: 342603-10-5.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-BOC-3-AMINO-5-METHOXYPYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: N-BOC-3-AMINO-5-METHOXYPYRIDINE(342603-10-5)
• EPA Substance Registry System: N-BOC-3-AMINO-5-METHOXYPYRIDINE(342603-10-5)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 342603-10-5(Hazardous Substances Data)

Usage

General Description

N-BOC-3-amino-5-methoxypyridine is a chemical compound with the molecular formula C12H16N2O3. It is an important building block in organic synthesis, commonly used in the pharmaceutical and agrochemical industries. N-BOC-3-AMINO-5-METHOXYPYRIDINE is a protected form of 3-amino-5-methoxypyridine, where the amine group is masked by the BOC (tert-butyloxycarbonyl) protecting group. The presence of the methoxy and amino groups makes N-BOC-3-amino-5-methoxypyridine a versatile intermediate for the synthesis of various heterocyclic compounds. N-BOC-3-AMINO-5-METHOXYPYRIDINE is often used in the production of pharmaceuticals and other bioactive molecules.

Upstream product

• 50720-12-2 3-bromo-5-methoxypyridine 
• 4248-19-5 tert-butyl carbazate 
• 625-92-3 3,5-dibromopyridine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 64436-92-6 3-amino-5-methoxypyridine 
• 7295-76-3 3-methoxypyridine 
• 36016-38-3 tert-Butyl N-hydroxycarbamate 

Downstream Products

• 709666-24-0 3-amino-5-methoxy-isonicotinic acid ethyl ester 
• 1045858-10-3 tert-butyl 5-methoxy-4-methylpyridin-3-ylcarbamate 
• 1202013-24-8 3-(3-chloro-4-fluorobenzyl)-5-methoxypyrido[3,4-d]pyrimidin-4(3H)-one 
• 1202013-26-0 3-(3-chloro-4-fluorobenzyl)-5-methoxypyrido[3,4-d]pyrimidin-4(3H)-one-7-oxide 
• 1202013-28-2 3-(3-chloro-4-fluorobenzyl)-5-methoxy-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidin-8-yl acetate 
• 1202013-30-6 3-(3-chloro-4-fluorobenzyl)-8-hydroxy-5-methoxypyrido[3,4-d]pyrimidin-4(3H)-one 
• 1202013-32-8 3-(3-chloro-4-fluorobenzyl)-5-methoxy-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidin-8-yl trifluoromethanesulfonate 
• 1202013-34-0 methyl 3-(3-chloro-4-fluorobenzyl)-5-methoxy-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidin-8-carboxylate 
• 1202013-36-2 methyl 3-(3-chloro-4-fluorobenzyl)-5-methoxy-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidin-8-carboxylate-7-oxide 
• 1202013-38-4 methyl 6-(acetyloxy)-3-(3-chloro-4-fluorobenzyl)-5-methoxy-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidin-8-carboxylate 
• 1185094-00-1 3-amino-5-methoxy-4-methylpyridine hydrochloride 
• 1192255-92-7 (3-methoxy[1,5]naphthyridin-4-yl)methanol 
• 1056877-13-4 3-methoxy-1,5-naphthyridine-4-carbaldehyde 
• 1056877-14-5 3-hydroxy[1,5]naphthyridine-4-carbaldehyde 

Relevant articles and documents

Synthesis of a 5-alkoxypyrido[3,4-d]pyrimidin-4(3H)-one derivative via directed ortho-metallation of a pyridine analogue

The synthetic strategy towards a 5-alkoxypyrido[3,4-d]pyrimidin-4(3H)-one is described, utilizing palladium catalyzed amination of a bromopyridine, and subsequent directed ortho-metallation/carboxylation as the key steps.

Process development of a novel azetidinyl ketolide antibiotic

Process development and the multikilogram synthesis of a novel azetidinyl ketolide antibiotic is described. Starting with clarithromycin, the eight-step synthesis features several telescoped operations and direct isolations, which results in a significant improvement in throughput and a major reduction in solvent usage and waste stream volume over the first scale-up campaign. Particular highlights of this effort include the development of an efficient synthesis of 3-hydroxy-1,5-naphthyridine-4-carbaldehyde via a Skraup process and engineering a robust final API synthesis. We also discovered a crystalline monotosylate salt that addressed significant formulation and degradation issues experienced when using the noncrystalline freebase.

HIV INTEGRASE INHIBITORS

Tricyclic compounds of Formula I are inhibitors of HIV integrase and inhibitors of HIV replication: (I) wherein G, T, R1, R2, R3A, R3B, R4A, R4B, R5A, R5B, R6A and R6B are defined herein. The compounds are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset or progression of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se (or as hydrates or solvates thereof) or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.